Medical Device and Healthcare Industry Trends — 2026-08-30
Samsung Biologics has announced a 3 trillion won rights offering to fund long-term growth investments, including peptide CDMO expansion and new facilities. Classys lowered its 2026 guidance due to sluggish domestic demand and integration delays in Brazil, but brokerages maintained a 62,000 won target price, pointing to a potential Brazilian market recovery. Meanwhile, the FDA is gathering industry feedback to establish a risk-free framework for generative AI medical devices, signaling a shifting global medtech regulatory landscape.
19 min read/15 sources
